vs
Side-by-side financial comparison of BELLRING BRANDS, INC. (BRBR) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $537.3M, roughly 1.2× BELLRING BRANDS, INC.). Royalty Pharma plc runs the higher net margin — 34.4% vs 8.1%, a 26.3% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 0.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 4.2%).
Bellring Brands, Inc. develops, manufactures and sells high-quality protein and functional nutritional products including ready-to-drink shakes, protein bars, powders and snacks. Its core brands Premier Protein, Dymatize and PowerBar serve health-conscious consumers and fitness enthusiasts across North America via retail, e-commerce and specialty channels.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
BRBR vs RPRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $537.3M | $622.0M |
| Net Profit | $43.7M | $214.2M |
| Gross Margin | 29.9% | — |
| Operating Margin | 14.6% | 62.4% |
| Net Margin | 8.1% | 34.4% |
| Revenue YoY | 0.8% | 4.8% |
| Net Profit YoY | -43.2% | 2.9% |
| EPS (diluted) | $0.36 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $537.3M | $622.0M | ||
| Q3 25 | $648.2M | $609.3M | ||
| Q2 25 | $547.5M | $578.7M | ||
| Q1 25 | $588.0M | $568.2M | ||
| Q4 24 | $532.9M | $593.6M | ||
| Q3 24 | $555.8M | $564.7M | ||
| Q2 24 | $515.4M | $537.3M | ||
| Q1 24 | $494.6M | $568.0M |
| Q4 25 | $43.7M | $214.2M | ||
| Q3 25 | $59.6M | $288.2M | ||
| Q2 25 | $21.0M | $30.2M | ||
| Q1 25 | $58.7M | $238.3M | ||
| Q4 24 | $76.9M | $208.2M | ||
| Q3 24 | $71.7M | $544.0M | ||
| Q2 24 | $73.7M | $102.0M | ||
| Q1 24 | $57.2M | $4.8M |
| Q4 25 | 29.9% | — | ||
| Q3 25 | 28.9% | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | 32.3% | — | ||
| Q4 24 | 37.5% | — | ||
| Q3 24 | 36.9% | — | ||
| Q2 24 | 36.8% | — | ||
| Q1 24 | 33.2% | — |
| Q4 25 | 14.6% | 62.4% | ||
| Q3 25 | 15.8% | 70.1% | ||
| Q2 25 | 8.2% | 36.3% | ||
| Q1 25 | 16.2% | 94.0% | ||
| Q4 24 | 21.6% | 60.9% | ||
| Q3 24 | 20.2% | — | ||
| Q2 24 | 21.7% | 50.2% | ||
| Q1 24 | 18.4% | -13.0% |
| Q4 25 | 8.1% | 34.4% | ||
| Q3 25 | 9.2% | 47.3% | ||
| Q2 25 | 3.8% | 5.2% | ||
| Q1 25 | 10.0% | 41.9% | ||
| Q4 24 | 14.4% | 35.1% | ||
| Q3 24 | 12.9% | 96.3% | ||
| Q2 24 | 14.3% | 19.0% | ||
| Q1 24 | 11.6% | 0.8% |
| Q4 25 | $0.36 | $0.49 | ||
| Q3 25 | $0.48 | $0.67 | ||
| Q2 25 | $0.16 | $0.07 | ||
| Q1 25 | $0.45 | $0.55 | ||
| Q4 24 | $0.59 | $0.46 | ||
| Q3 24 | $0.54 | $1.21 | ||
| Q2 24 | $0.56 | $0.23 | ||
| Q1 24 | $0.43 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.1M | $618.7M |
| Total DebtLower is stronger | $1.2B | $9.0B |
| Stockholders' EquityBook value | $-510.7M | $9.7B |
| Total Assets | $1.1B | $19.6B |
| Debt / EquityLower = less leverage | — | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $64.1M | $618.7M | ||
| Q3 25 | $71.8M | $938.9M | ||
| Q2 25 | $43.7M | $631.9M | ||
| Q1 25 | $28.1M | $1.1B | ||
| Q4 24 | $49.6M | $929.0M | ||
| Q3 24 | $70.8M | $950.1M | ||
| Q2 24 | $72.6M | $1.8B | ||
| Q1 24 | $79.3M | $843.0M |
| Q4 25 | $1.2B | $9.0B | ||
| Q3 25 | $1.1B | $8.9B | ||
| Q2 25 | $1.0B | $8.0B | ||
| Q1 25 | $953.7M | $7.6B | ||
| Q4 24 | $833.4M | $7.6B | ||
| Q3 24 | $833.1M | $7.6B | ||
| Q2 24 | $832.7M | $7.6B | ||
| Q1 24 | $832.4M | $6.1B |
| Q4 25 | $-510.7M | $9.7B | ||
| Q3 25 | $-453.9M | $9.6B | ||
| Q2 25 | $-309.9M | $9.5B | ||
| Q1 25 | $-254.1M | $9.8B | ||
| Q4 24 | $-146.6M | $10.3B | ||
| Q3 24 | $-205.9M | $10.3B | ||
| Q2 24 | $-243.2M | $9.8B | ||
| Q1 24 | $-247.7M | $9.9B |
| Q4 25 | $1.1B | $19.6B | ||
| Q3 25 | $941.0M | $19.3B | ||
| Q2 25 | $993.7M | $18.3B | ||
| Q1 25 | $947.5M | $17.6B | ||
| Q4 24 | $885.2M | $18.2B | ||
| Q3 24 | $837.0M | $18.0B | ||
| Q2 24 | $804.1M | $17.7B | ||
| Q1 24 | $765.0M | $16.1B |
| Q4 25 | — | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.1M | $827.1M |
| Free Cash FlowOCF − Capex | $-7.3M | — |
| FCF MarginFCF / Revenue | -1.4% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | -0.07× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $246.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.1M | $827.1M | ||
| Q3 25 | $169.1M | $702.6M | ||
| Q2 25 | $40.3M | $364.0M | ||
| Q1 25 | $48.2M | $596.1M | ||
| Q4 24 | $3.0M | $742.5M | ||
| Q3 24 | $40.1M | $703.6M | ||
| Q2 24 | $69.0M | $658.2M | ||
| Q1 24 | $16.3M | $664.6M |
| Q4 25 | $-7.3M | — | ||
| Q3 25 | $168.1M | — | ||
| Q2 25 | $38.5M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $38.9M | — | ||
| Q2 24 | $68.9M | — | ||
| Q1 24 | $16.0M | — |
| Q4 25 | -1.4% | — | ||
| Q3 25 | 25.9% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 13.4% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | -0.07× | 3.86× | ||
| Q3 25 | 2.84× | 2.44× | ||
| Q2 25 | 1.92× | 12.06× | ||
| Q1 25 | 0.82× | 2.50× | ||
| Q4 24 | 0.04× | 3.57× | ||
| Q3 24 | 0.56× | 1.29× | ||
| Q2 24 | 0.94× | 6.45× | ||
| Q1 24 | 0.28× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRBR
| Shakesandotherbeverages | $432.4M | 80% |
| Powders | $92.1M | 17% |
| Other Products | $12.8M | 2% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
